Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. (NASDAQ:VCNX) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totalling 57,900 shares, a drop of 37.8% from the August 15th total of 93,100 shares. Based on an average daily trading volume, of 76,000 shares, the short-interest ratio is presently 0.8 days. Approximately 7.4% of the shares of the stock are sold short.

Insider Buying and Selling

In related news, Director Albert Friedberg purchased 200,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were bought at an average price of $6.15 per share, with a total value of $1,230,000.00. Following the completion of the acquisition, the director now owns 762,415 shares of the company’s stock, valued at $4,688,852.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders acquired 203,753 shares of company stock worth $1,247,255. Corporate insiders own 51.50% of the company’s stock.

Institutional Investors Weigh In On Vaccinex

An institutional investor recently raised its position in Vaccinex stock. AIGH Capital Management LLC grew its holdings in Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 108,958 shares of the company’s stock after purchasing an additional 50,593 shares during the period. AIGH Capital Management LLC owned approximately 6.90% of Vaccinex worth $707,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 50.11% of the company’s stock.

Vaccinex Price Performance

Shares of Vaccinex stock opened at $5.61 on Friday. Vaccinex has a 12-month low of $4.21 and a 12-month high of $51.98. The firm has a market capitalization of $9.71 million, a PE ratio of -0.07 and a beta of 0.99. The stock’s fifty day moving average is $5.83 and its 200-day moving average is $6.33.

Vaccinex (NASDAQ:VCNX) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($3.10) EPS for the quarter. The business had revenue of $0.23 million for the quarter.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.